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Introduction: Delayed graft function (DGF) remains a significant and detrimental postoperative phenomenon
following living-related renal allograft transplantation, with a published incidence of up to 15%. Early therapeutic
vasodilatory interventions have been shown to improve DGF, and modifications to immunosuppressive regimens
may subsequently lessen its impact. This pilot study assesses the potential applicability of perioperative non-invasive
cardiac output monitoring (NICOM), transit-time flow monitoring (TTFM) of the transplant renal artery and
pre-/perioperative thromboelastography (TEG) in the early prediction of DGF and perioperative complications.
Methods: Ten consecutive living-related renal allograft recipients were studied. Non-invasive cardiac output monitoring
commenced immediately following induction of anaesthesia and was maintained throughout the perioperative period.
Doppler-based TTFM was performed during natural haemostatic pauses in the transplant surgery: immediately following
graft reperfusion and following ureteric implantation. Central venous blood sampling for TEG was performed following
induction of anaesthesia and during abdominal closure.
Results: A single incidence of DGF was seen within the studied cohort and one intra-operative (thrombotic) complication
noted. NICOM confirmed a predictable trend of increased cardiac index (CI) following allograft reperfusion (mean
CI - clamped: 3.17 ± 0.29 L/min/m2, post-reperfusion: 3.50 ± 0.35 L/min/m2; P < 0.05) mediated by a significant reduction
in total peripheral resistance. Reduced TTFM at the point of allograft reperfusion (227 ml/min c.f. mean; 411 ml/min
(95% CI: 358 to 465)) was identified in a subject who experienced intra-operative transplant renal artery thrombosis. TEG
data exhibited significant reductions in clot lysis (LY30 (%): pre-op: 1.0 (0.29 to 1.71), post reperfusion 0.33 (0.15 to 0.80);
P = 0.02) and a trend towards increased clot initiation following allograft reperfusion.
Conclusions: Reduced renal arterial blood flow (falling without the 95% CI of the mean), was able to accurately predict
anastomotic complications within this pilot study. TEG data suggest the emergence of a prothrombotic state, of uncertain
clinical significance, following allograft reperfusion. Abrogation of characteristic haemodynamic trends, as determined by
NICOM, following allograft reperfusion may permit prediction of individuals at risk of DGF. The findings of this pilot study
mandate a larger definitive trial to determine the clinical applications and predictive value of these technologies.
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Renal transplantation is the gold standard form of renal
replacement therapy [1], with highly significant survival
and economic benefits over haemodialysis and peritoneal
dialysis.
Aside from acute rejection, the most important post-
operative sequela following transplantation is delayed
graft function (DGF). There is no unified definition for
DGF; indeed, a recent systematic review demonstrated
over 18 published definitions [2]. However, DGF is gen-
erally defined in the context of the need for dialysis
post-transplant, and/or a proportional or absolute inad-
equate fall in serum creatinine level at a set time point
after transplantation. Although rates of DGF in live-
donor transplantation are lower than in deceased-donor
recipients, the published incidence can be as high as
15%, with an associated doubling in the risk of acute re-
jection and potential reduction in overall graft survival
duration [3,4].
The underlying causes of DGF are complex and multi-
factorial, but are essentially due to warm ischaemic in-
jury, hypothermic injury and reperfusion injury. In the
context of live donation, where warm ischaemic time
and cold storage duration are short, minimisation of re-
perfusion injury is the primary target for amelioration
of DGF. The importance of systolic and diastolic blood
pressure at the time of reperfusion of renal transplants is
well established [5,6]. Furthermore, several vasodilatory
therapeutic interventions have been shown to improve
DGF both clinically and experimentally [7].
Identification of recipients at risk of developing DGF
allows modification of immunosuppressive regimens by
sparing or minimisation of calcineurin inhibitors, and
use of thymoglobulin and mycophenolate. There is evi-
dence that these measures can significantly reduce the im-
pact of DGF [7-9].
Cardiac output (CO) monitoring during surgical pro-
cedures offers a means of ensuring adequate systemic
perfusion and is superior to the observation of basic car-
diovascular parameters, pulse rate and blood pressure,
alone [10]. Real-time non-invasive assessment of CO al-
lows the anaesthetist to utilise a range of inotropic and
vasoactive medications intra-operatively to optimise the
cardiovascular status of the transplant recipient, thereby
maintaining adequate renal arterial blood flow to the
allograft following reperfusion and avoiding the risks of
Swann-Ganz catheterization [11].
Cardiac output
Non-invasive cardiac output monitoring (NICOM) based
on the principles of bioimpedance plethysmography and
more recently bioreactance plethysmography, has been
used to provide risk-free real-time data (avoiding the po-
tential morbidities conferred by invasive techniques likeSwann-Ganz catheters and oesophageal Doppler mon-
itoring) [12]. For bioreactance based NICOM™ (Cheetah
Medical Inc, Portland, Oregon 97201, USA), sensors are
placed on the patient’s chest to deliver a low voltage alter-
nating electrical current of known amplitude and fre-
quency across the thorax.
Bioreactance NICOM™, has been validated against in-
vasive Swann-Ganz CO monitoring without the signifi-
cant associated risks [13].
Renal blood flow
Renal blood flow (perfusion) may be measured directly
by Doppler-based transit-time flow monitoring (TTFM)
intra-operatively. A similar implantable technology has
been shown to be a feasible technique for identifying
at-risk organs in the post-operative period, potentially
saving precious kidneys and reducing the frequency of
unnecessary explorative procedures [14].
Thromboelastography
Thromboelastography (TEG) has been proven to be of
significant value in the prediction of hyper- and hypo-
coagulable states for patients undergoing hepatic trans-
plantation and coronary artery bypass graft surgery, in
addition to having an established role in the monitoring
of patients receiving intravenous heparin [15]. However,
its role is as-yet undefined in the prediction of clotting-
related complications of living-related renal transplant-
ation, which may range from severe haemorrhage to
thrombosis and failure of the renal allograft. TEG assess-
ment of living related transplant recipients on induction
may thus confer significant advantages in the context of
diagnosis and management of occult clotting defects. A
growing body of evidence suggests that TEG is superior
to routine laboratory tests in guiding intra-operative co-
agulation management [16].
Aim
This pilot study aims to assess the potential applicability
of perioperative non-invasive cardiac output monitoring,
transit-time flow monitoring (TTFM) of the transplant
renal artery and pre-/perioperative thromboelastograph
(TEG) in the early prediction of DGF and perioperative
complications for living-related renal transplantation.
Positive results arising from this study will form the basis
or justification for future prospective research in this im-
portant area.
Methods
Ethical approval for this pilot study was granted by the
Black Country Research Ethics Committee and NHS/HSC
Research and Development offices. Informed consent for
participation in the study was granted by all subjects,
there were no refusals of consent.
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for the study. HLA-incompatible allograft recipients were
not excluded from the study due to proven excellent out-
comes achieved using a previously described immunosup-
pressive regimen [17]. University Hospitals Coventry and
Warwickshire (UHCW) NHS Trust practices parallel lap-
aroscopic donor nephrectomy and retroperitoneal expos-
ure (of the recipient’s external iliac artery and vein), in
adjacent theatres, for all living-related renal transplant-
ation. Each surgical team (donor and recipient) comprised
a combination of two consultant surgeons, or a single
consultant and an experienced registrar/associate special-
ist. As a consequence, warm ischaemic time was negli-
gible for the donated organs, limited to the time required
for extraction of the kidney immediately following stapl-
ing of the vascular pedicle. The harvested organ was
then immediately received by a member of the transplant
team, packed in ice and perfused with cold histidine-
tryptophan-ketoglutarate (HTK) solution prior to work-
bench preparation and transfer into the adjoining theatre
for transplantation. Cold ischaemic time was <2 hours for
all studied cases.
Pre-determined exclusion criteria for this study in-
cluded individuals receiving allografts with multiple
renal arteries and cases where laparoscopic donor neph-
rectomy was converted to open nephrectomy (in lieu of
prolonged warm ischaemic time). Only one individual
was prospectively excluded from the study due to known
duplex transplant renal arteries.
Ten consecutive living-related renal transplantation
recipients were prospectively studied at UHCW NHS
Trust. All patients received immunosuppression with
tacrolimus 0.15 mg/kg/day (2 days before transplant),
azathioprine 1.5 mg/kg, or mycophenolate 1000 mg bd
started on the day of transplant or at the start of pre-
transplant plasmapheresis. Methylprednisolone 500 mg
and basiliximab 20 mg were administered to all subjects
intra-operatively. At surgery, allograft vascular anasto-
moses were to the external iliac vein and artery in all cases.
No modifications to the anaesthetic or surgical technique
were made as a consequence of participation in this study.
The results of all pre-operative haematology, biochem-
istry and radiological investigations (for 24 h prior to
surgery) were collected from the Trust’s Clinical Results
Reporting System (CRRS) software. Similarly, postopera-
tive data were recorded for a period of 7 days.
Non-invasive cardiac output monitoring (NICOM™;
Cheetah Medical Incorporated, Vancouver, WA, USA)
was applied following induction of anaesthesia and left in
situ, actively recording, until the subject was discharged
from theatre recovery to the transplant surgical ward.
Transit-time flow measurement of the transplant renal
artery was performed using a Doppler flow probe (Veri-Q;
Medi Stim ASA, Oslo, Norway). Measurements wereperformed by the principal surgeon, during two natural
intra-operative haemostatic pauses; immediately following
allograft reperfusion and after cystoureteric anastomosis.
For the purposes of this pilot study, the development of
DGF was defined as the requirement for dialysis within
seven days of allograft transplantation.
NICOM™
Bioreactance is often compared with bioimpedance, an
older technology used to determine cardiac output. Bior-
eactance and bioimpedance are conceptually similar to the
principles of frequency modulation (FM) and amplitude
modulation (AM) radio. With FM radio, signal detection is
based on changes in signal frequency rather than changes
in signal amplitude, allowing for greater fidelity in the ob-
tained signal, as amplitude decays exponentially with dis-
tance from source, whereas frequency remains constant
within a given medium. FM enables significant advantages
in filtering noise, for example noise coming from other
electronic or physiologic emitters. This is why FM-based
systems offer superior performance compared to AM [18].
Prior to the induction of anaesthesia, the NICOM™ de-
vice was programmed with the patient’s unique identify-
ing number, age (yrs), sex, height (m) and weight (kg),
facilitating calculation of body surface area (BSA; m2).
Measured haemodynamic data (pulse rate, cardiac output/
index) were constantly monitored throughout surgery and
recovery (data points automatically recorded at 1-min in-
tervals). Non-invasive blood pressure (NIBP) monitoring
was set to measure every 5 minutes, allowing calculation
and collection of total peripheral resistance (TPR) and
TPR index (TPRI) at equivalent intervals.
Non-invasive cardiac output monitoring was applied
by a trained investigator immediately upon entering the
operating theatre, prior to the commencement of surgery.
The adhesive pre-wired sensors were placed as per device
instructions-for-use and in addition to routine anaesthetic
monitoring equipment.
Transit-time flow measurement
Renal arterial blood flow (RBF) may now be directly mea-
sured intra-operatively using a validated, Doppler-based
transit time flow measurement (TTFM) device (VeriQ,
Medi-Stim, Oslo, Norway). Transit time is measured as the
time spent by an ultrasound signal that travels between
two synchronously placed piezoelectric crystals via a me-
tallic reflector bracket situated on the opposite side of the
arterial wall. Blood volume flow (ml/min) calculation is de-
rived from the time difference between ultrasound signals
travelling with and against the direction of blood flow
within the vessel. This method has been validated against
direct measurements of blood flow [19].
The appropriate size of the probe was determined by
measurement of the transplant arterial diameter. The probe
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the operating surgeon. Flow velocity readings (ml/min)
and pulsatility index (PI) data were subsequently recorded,
by a named investigator, at 15-sec intervals for a period of
3 minutes. Two datasets were collected for each patient:
immediately following graft reperfusion and following
cystoureteric anastomosis.
Thromboelastography
A pre-operative central venous 5-ml blood sample was
drawn prior to the commencement of surgery for the
purposes of thromboelastographic analysis and immedi-
ately processed by a trained senior perfusionist. A post-
reperfusion central venous 5-ml blood sample was similarly
drawn and processed (at the point of abdominal closure, in
each case) for comparison.
Follow-up
One-year follow-up data including graft failure (a return
to dialysis dependence), serum creatinine levels, haemor-
rhagic and thrombotic graft complications, incidences of
rejection and venous thrombo-embolism were recorded
and analysed in the context of NICOM™, TTFM, TEG
and phlebotomy data findings. Data were collected from
CRRS and the patient case notes (including clinic and
discharge letters over the 1-year period).
Statistical analysis
Data were tabulated in Microsoft Excel (Microsoft, CA,
USA) spreadsheets and data analysis performed using
GraphPad 4 (GraphPad, La Jolla, CA, USA) Statistical
Software. Numerical data were assessed using a D’Agostino
and Pearson omnibus normality test and the appropriate
parametric/non-parametric comparative tests selected (in-
dicated within the text). Categorical data were assessed by
Fisher’s exact test. Specific data describing cardiac index
(CI) modulation following reperfusion utilized a predeter-
mined post-hoc analysis of the NICOM™ data, including CI
data-points for 10 minutes pre- and 10 minutes post-
allograft reperfusion. Data describing SBP, TPR and TPRI
(collected automatically at 5-minute intervals) modulation
at reperfusion similarly utilized a predetermined post-hoc
analysis of the NICOM™ data, permitting use of the imme-
diately pre-reperfusion and post-reperfusion NIBP values.
Significance was attributed at P <0.05.
Power calculations for prospective definitive studies
were performed by a Z-test, utilising the statistical data
from this pilot study.
Results
Ten appropriate consecutive patients (P1 to P10) under-
going living-related renal transplantation were studied.
Demographic data are shown in Table 1.Applicability
NICOM™ monitoring was successfully achieved in 100%
of the studied subjects using the agreed-upon protocol.
NICOM™ haemodynamic monitoring was subject to
sensor-interference only due to prolonged use of coagu-
lation monopolar diathermy during operative (retroperi-
toneal in all cases) exposure of the iliac vessels. The
mean period of data loss during dissection was 5.4 min
(95% CI: 2.7 to 8.1) and was consistent with the sensor
interference noted by concurrent bioimpedance-based
ECG monitoring equipment.
Concomitant use of anaesthetic-monitoring equipment
and NICOM™ was best achieved by placing the cranially
situated NICOM™ pads laterally to the right upper limb
(red) and left upper limb (yellow) adhesive ECG pads.
This avoided interference of the bioimpedance-based
ECG monitoring. No reciprocal NICOM™ interference
was noted in the above orientation.
One episode of NICOM™-monitoring failure (and sub-
sequent data loss; P6) was noted during postoperative
patient transfer to the recovery bed. This was due to
shearing of a pre-wired NICOM™ sensor lead during trans-
fer, mandating replacement of a pair of adhesive sensor
pads and re-calibration of the device (achieved within
12 minutes) to continue monitoring.
TTFM monitoring was achieved in 100% of the stud-
ied subjects as per study protocol. The technique was
considered technically straightforward, acceptable and
repeatable by each of the principle surgeons.
TEG analysis was performed as per protocol in 90% of
patients, but was omitted in an individual who did not
routinely receive perioperative internal jugular vein (IJV)
central venous access.
Pre-operative and 24-h postoperative mean blood re-
sults are tabulated (Table 2). Patient five (P5) was con-
firmed to exhibit delayed graft function (DGF), requiring
haemodialysis within one-week of transplantation; this sub-
ject’s serum creatinine concentration was 243 mcmol/L
7 days P5 exhibited postoperative increases in urea
(5 mmol/L to 8.7 mmol/L) and creatinine (245 μmol/L
to 295 μmol/L), within 24 h of surgery (Figures 1 and 2),
opposing significant biochemical trends shown by non-
DGF transplants (Table 2).
NICOM™
Predictable haemodynamic trends were noted during key
surgical steps.
Cardiac index increased following transplant-reperfusion
(mean CI - clamped: 3.17 ± 0.29 L/min/m2, post-reperfusion:
3.50 ± 0.35 L/min/m2; P <0.05 - paired t-test; Figure 3)
mediated by a reduction in total peripheral resistance
index (mean TPRI-clamped: 2240 ± 251dynes.sec/cm5/m2,
post-reperfusion: 1985 ± 166 dynes.sec/cm5/m2; P <0.05 -
paired t-test; Figure 4) and associated with a reduction of


















P1 30 161 64 1.67 24.7 White European HDb (fistula) N −/+ Henoch-Schonlein
Purpura
P2 45 177 101 2.18 32.2 White European Pre-dialysis N −/− ?Hypertensive
nephropathy
P3 41 179 77 1.96 24.0 White European Pre-dialysis N −/− FSGSc
P4 24 157 50.4 1.49 20.4 White European Pre-dialysis N +/+ ?Hypertensive
nephropathy
P5a 41 157 66.4 1.67 26.9 South Asian HDb (vascath) N −/+ DM nephropathy





P7 58 168 58.8 1.67 20.8 South Asian HDb (fistula) N +/+ Membranous
nephropathy
P8 23 161 49.6 1.5 19.1 White European CAPD N −/− Chronic pyelonephritis
P9 48 169 77.4 1.88 27.1 White European HDb (fistula) N −/− IgA nephropathy
P10 37 189 90.6 2.18 25.4 White European Pre-dialysis N −/− IgA nephropathy
aP5 (highlighted) demonstrated DGF at 7-days post-operatively. bHD, haemodialysis; cFSGS, focal segmental glomerulosclerosis; dAIT, antibody incompatible transplantation.
Of the individuals studied, one incidence of DGF was noted (10%; P5). One intra-operative complication (10%; P3; thrombus at the arterial anastomosis, requiring
thrombectomy and revision of the anastomosis) identified. One patient was postoperatively commenced on anti-rejection therapy (anti-thymoglobulin antibody)
(10%; P7; within the period of follow-up, but did not demonstrate DGF).
Table 2 Pre-operative and Postoperative (Day 1) mean values for routine haematological and biochemical
investigations of all studied living-related transplant recipients
Pre-op Day 1 Paired t-test P value
Mean 95% CI Mean 95% CI
Na (mmol/L) 142 140-144 140 137-144 0.315
K (mmol/L) 4.9 4.4-5.4 5.1 4.7-5.6 0.190
Ur (mmol/L) 14.9 8.5-21.3 9.9 7.1-12.8 0.055
Cr (μmol/L) 494 361-628 207 150-263 0.001
WCC (109/L) 6.3 5.1-7.5 10.4 8.4-12.4 0.001
Hb (g/dL) 12.1 10.7-13.4 10.12 8.8-11.4 <0.001
Plt (109/L) 204 158-249 186 128-243 0.137
Alb (g/L) 42 39-46 33 30-37 <0.001
Bili (μmol/L) 8 6.5-9.8 6.7 4.9-8.5 0.214
ALT (IU/L) 120 14-25 17 12-22 0.483
Ca (adj) (mmol/L) 2.24 2.08-2.40 2.15 2.01-2.30 0.013
Al Phos (IU/L) 95 22-168 88 16-160 0.127
PT (sec) 11.7 10.9-12.6 12.0 11.3-12.6 1.0
INR 1.1 1.0-1.2 1.1 1.1-1.2 1.0
APTTr 1.08 1.03-1.12 1.01 0.96-1.06 0.104
Mg (mmol/L) 0.87 0.77-0.97 0.74 0.65-0.83 0.003
Phos (mmol/L) 1.6 1.49-1.76 1.62 1.35-1.89 0.963
CRP (mg/L) 8 1-14 19 5-32 0.032
Na, sodium; K, potassium; Ur, urea; Cr, creatinine; WCC, white cell count; Hb, haemoglobin; Plt, platelet count; Alb, albumin; Bili, bilirubin; ALT, alanine
transaminase; Ca (adj), adjusted calcium; Al Phos, alkaline phosphatase; PT, prothrombin time; INR, international normalized ratio; APTTr, activated partial
thromboplastin time ratio; Mg, magnesium; Phos, phosphate; CRP, C-reactive protein.
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Figure 1 Pre-operative versus post-operative day 1 serum creatinine.
The left hand pair of bars represent mean (95% CI) creatinine for the ten
studied subjects (**P <0.01). The right hand pair of bars represent
individual data for patient 5 (P5), who experienced delayed graft function.
Figure 3 Cardiac index (CI) during (external iliac artery and
vein) clamping and following reperfusion of the allograft
(declamping). The left hand scatter diagram displays the mean
(95% CI) cardiac index during vessel clamping for the ten studied
subjects. The right hand scatter diagram shows mean (95% CI)
cardiac index at reperfusion. (*P <0.05 for mean values). Data for P5,
who experienced DGF, are represented by the outlined data points
in each diagram.
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6.7 mmHg, post-reperfusion: 116 ± 4.3 mmHg; P <0.05 -
paired t-test; Figure 5).
These characteristic haemodynamic trends (TPRI and
SBP) were abrogated in the individual who later experi-
enced delayed graft-function (P5) (Figures 4,5).Figure 2 Pre-operative versus post-operative day 1 serum urea.
The left hand pair of bars represent mean (95% CI) urea for the ten
studied subjects (P= 0.055). The right hand pair of bars represent
individual data for patient 5 (P5), who experienced delayed graft function.TTFM
Mean transplant arterial blood flow at reperfusion: 411 ml/
min (95% CI: 358 to 465) and following cysto-ureteric anas-
tomosis: 480 ml/min (95% CI: 378 to 581; P = 0.11 - paired
t-test). By comparison, a flow rate of only 227 ml/min wasFigure 4 Total peripheral resistance index (TPRI) during
(external iliac artery and vein) clamping and following
reperfusion of the allograft (declamping). The left hand scatter
diagram displays the mean (95% CI) total peripheral resistance (TPRI)
during vessel clamping for the ten studied subjects. The right hand
scatter diagram shows mean (95% CI) TPRI at reperfusion. (*P <0.05
for mean values). Data for P5 who experienced DGF are represented
by the outlined data-points in each diagram.
Figure 6 Mean transplant renal artery flow and 95% CI (left)
following allograft reperfusion and (right) following ureteric
anastomosis. The initial data point for P3, who demonstrated
anastomotic thrombosis at the point of initial reperfusion, is shown
as an encircled point on the left-hand scatter diagram.
Figure 5 Mean systolic blood pressure (SBP) during (external
iliac artery and vein) clamping and following reperfusion of the
allograft (declamping). The left hand scatter diagram displays the
mean (95% CI) SBP during vessel clamping for the ten studied
subjects. The right hand scatter diagram shows mean (95% CI) SBP
at reperfusion. (*P <0.05 for mean values). Data for P5, who
experienced DGF, are represented by the outlined data points in
each diagram.
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(Figure 6).
Thromboelastography
TEG data are displayed in Table 3. All pre-operative
TEG values fell within the manufacturer’s stated nor-
mal range for clot initiation, propagation and lysis.
Comparative paired analysis between pre-operative
and post-reperfusion samples for the studied group,
however, demonstrated a significant reduction on
proportionate clot lysis in the first 30 and 60 minutes
(after clot formation: LY30 and LY60 values), suggest-
ing a reduction in fibrinolytic activity toward the end
of the surgery, following allograft implantation. There
was also a trend (nonsignificant) toward reduced
reaction-time (R-value; representative of increased ac-
tivation of the coagulation cascade, P = 0.07) for the
post-reperfusion samples.
Follow-up at 1 year
Graft failure at one year follow-up was limited to one indi-
vidual (P1: 10% of the studied cohort), a consequence of
chronic antibody-mediated rejection onset at 9-months,
requiring a return to haemodialysis.
Median creatinine at six months follow-up was
115 μmol/L (interquartile range 93.5 to 131.5) and at
one-year follow-up was 118.5 μmol/L (interquartile
range 94.0 to 131.0).Early acute rejection was seen in five subjects (P1, P5,
P6, P7 and P9; 50% of studied subjects) and successfully
treated in each case with variable immunological regi-
mens (Table 4). There were no significant differences in
CI, TPRI or SBP during the clamped and reperfusion
(de-clamped) phases of surgery among individuals ex-
periencing acute early rejection and those who did not
upon subgroup analysis. Similarly, no detectable differ-
ences in renal artery blood flow at reperfusion or follow-
ing ureteric implantation were evident between these
subgroups. Pre-operative thromboelastography demon-
strated a trend (nonsignificant) towards increased reac-
tion time (R(rejection) = 5.06 min (95% CI: 4.08 to 6.04)
versus R(no rejection) = 2.06 min (95% CI, 1.78 to 5.89);
P = 0.069, unpaired t-test) and increased clot lysis at
60 minutes (LY60(rejection) = 7.6% (95% CI: 6.14 to 9.06)
versus LY60(no rejection) = 6.4% (95% CI: 5.77 to 7.07); P =
0.074, unpaired t-test) for individuals who suffered early
acute rejection compared to those who did not. A one-
sample Z-test determined that the required study sample
size to confirm or refute this observed trend would be
nine patients in each arm, a minimum of n = 18 subjects.
There were no further incidences of thromboembolic
graft complications at one year follow-up and no inci-
dences of venous thromboembolism (VTE) reported.
One patient (P1) experienced a post-operative haemor-
rhagic complication, requiring the percutaneous drainage
of a symptomatic (peri-allograft) retroperitoneal haema-
toma. The treatment of this was successful, and no further
collections developed.
Table 3 Paired t-test analysis of thromboelastography (TEG) values derived from pre-operative and post-reperfusion
(paired) samples in renal transplant patients (n = 8)
Pre-operative samples (value, 95% CI) Post-reperfusion samples (value, 95% CI) Paired t-test P value
Reaction time (R; min) 7.0 (6.3-7.8) 6.4 (5.9-6.9) 0.07
Kinetic time (K; min) 2.10 (1.5-2.7) 2.16 (1.8-2.6) 0.84
Alpha angle (degrees) 62.4 (56.6-68.2) 59.5 (52.2-66.8) 0.71
Maximum amplitude (MA; mm) 67.4 (61.3-73.6) 65.3 (57.9-72.7) 0.98
G-value 11.3 (8.3-14.3) 10.4 (6.6-14.2) 0.84
LY30 (%) 1.0 (0.29-1.71) 0.33 (0.15-0.80) 0.02
LY60 (%) 3.6 (1.7-5.5) 2.0 (0.5-3.5) 0.02
Amplitude (A; mm) 61.8 (54.4-69.3) 61.6 (53.3-69.8) 0.45
Coagulation index (CI) −0.16 (−1.9-1.59) −0.25 (−1.7-1.1) 0.52
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The data contained within this pilot study allows power/
sample size calculations to be performed, using the one-
sample Z-test, for the purposes of ongoing prospective
research.NICOM™
A study with 80% power to detect a significant (P <0.05)
difference in CI between non-DGF and DGF patients
would require haemodynamic data for ten patients exhi-
biting delayed graft function. Based upon the findings of
this work (DGF occurred in 10% of patients), and rates
of DGF apparent in the current literature (up to 15% of
transplants), an n value of 67 to 100 (total) subjects
would be required.
However, detection of an equivalent statistical difference
in TPRI data would require data for three patients with
DGF, equating to a maximum of n = 30 studied subjects.TTFM
A study with 80% power to confirm a significant (P <0.05)
difference in renal artery blood flow between post-
anastomotic measurement and post ureteric-implantation
measurement was achievable with n = 10 subjects. How-
ever, from this study, one of the 10 studied subjects (10%)
was found to have anastomotic complications, requiring
surgical revision. The markedly reduced flow rate observed
in this individual may be confirmed as statistically sig-
nificant in a study exhibiting two patients with anas-
tomotic complications and would thus require a minimum
of n = 20 subjects.TEG
A study with 80% power to confirm a significant (P <0.05)
difference in reaction time (R-value) between pre-operative
and post-reperfusion TEG samples would require n = 21
subjects.Discussion
Perioperative NICOM™ monitoring, TEG and intra-
operative TTFM, in the context of this study, are feasible
adjuncts to living-related renal transplantation surgery,
with no apparent or potential detrimental effects to the
patient.
Characteristic and significant haemodynamic trends
were noted by NICOM™ monitoring at graft reperfusion;
an increase in CI was noted concurrently with a reduc-
tion in TPRI. Systolic blood pressure was also noted to
reduce immediately following allograft reperfusion. For
the individual who subsequently developed DGF, an in-
crease in SBP and TPRI was noted following reperfusion,
abrogating the established trends. However, a modest in-
crease in CI prevailed in this subject. This pilot study
was insufficiently powered to demonstrate significant re-
lationship between changes in TPRI and SBP and the de-
velopment of DGF, however it supports the need for
further research to assess a possible predictive role of such
cardiac output monitoring in the intra-operative predic-
tion of susceptible individuals. These findings may also be
supported by the measurement of biochemical markers
on post-operative day 1; a failure to improve creatinine
clearance at this juncture was also apparent for P5, who
was later determined to exhibit DGF. Further assessment
of this relationship may be of value. These clinical findings
may facilitate an early decision to adopt calcineurin
inhibitor-sparing immunosuppressive regimens, poten-
tially minimizing the impact of DGF [7-9,20].
TTFM data indicated a median transplant-arterial blood
flow of 430 ml/min (95% CI: 351 to 472) following allo-
graft reperfusion. P5 data points fell comfortably within
this confidence interval, suggesting that the absolute flow-
rate values have no obvious application in the prediction
of DGF within the limitations of this pilot study. However,
one individual (P3) experienced intra-operative throm-
bosis of the transplant renal artery (at the anastomosis)
and upon assessment, demonstrated an average flow rate
of only 228 ml/min (lying outside the lower 95% CI for
Table 4 One year follow-up and outcome data for the studied group of ten living-related renal transplant recipients
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eCampath, no benefit
P2 ✗ No ✗ No No 120 111 No
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P4 ✗ No ✗ No No 67 79 No
P5 ✓ ✗ Yes Antibody mediated acute
rejection cause of cDGF
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P8 ✗ No ✗ No No 129 129 No
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intra-operative appearance of the allograft at reperfusion
and facilitated the decision to immediately revise the anas-
tomosis, perform thrombectomy and ultimately salvage
the transplanted kidney. Again, significance cannot be at-
tached to the difference in flow rates described above;
however, it mandates further investigation. With a suffi-
ciently powered study, a quantifiable flow rate associated
with graft anastomotic complications and thus graft failure
may be achieved, as is the case in AV-fistula surgery [21]
and CABG [22-24]. This may, in turn, form an evidence
base for a guideline of minimum acceptable flow rate in
living-related transplant surgery, ultimately salvaging pre-
cious donor allografts. From the data of this pilot study,
the authors suggest a putative minimum acceptable flow
rate at reperfusion of approximately 350 ml/min as a cut-
off for anastomotic exploration and revision (that is, out-
side the lower 95% CI of our pilot data).
Within this pilot study, all pre-operative thromboelas-
tography values relating to the activation of the coagula-
tion cascade, thrombus initiation/propagation and lysis
fell within the manufacturer’s ‘normal’ range and implies
little or no application for this test in the prediction of
individuals susceptible to DGF. The authors would, how-
ever, recommend the ongoing use of pre-operative TEG
and further, larger, studies of its applicability within this
context. At present, no clear data exist to describe the
outcomes of individuals with abnormal TEG values prior
to renal transplantation and a valid, predictive clinical role
for this simple test may yet become apparent. Moreover,
paired analysis of pre-operative and post-reperfusion TEG
data demonstrated a significant reduction in fibrinolysis
and a trend towards increased activation of the coagula-
tion cascade toward the end of the renal transplantation
surgery. These findings may be considered consistent with
the findings of previous work in kidney/pancreas trans-
plantation [25]. By implication, therefore, a potentially hy-
percoagulable state may thus arise as a consequence of
living-related renal transplantation surgery, although our
data do not allow speculation as to whether this results
from the overall surgical insult or as a consequence of
allograft implantation and reperfusion. Our study protocol
did not permit further TEG analysis in the post-operative
phase, thus potentially missing evidence of perioperative
hypercoagulability. The clinical significance of these data
are unclear; therefore, larger prospective studies are re-
quired to assess these findings in the context of short- and
medium-term thromboembolic outcomes and allograft
complications. Modification of the study methodology to
include post-operative TEG measurements may further
define the extent and significance of a hypercoagulable
state, and correlation of these data with the occurrence of
VTE or thromboembolic graft complications, may provide
a clinical context and relevance to future research.One year follow-up identified a 10% rate of graft fail-
ure, a 10% rate of haemorrhagic complications (retro-
peritoneal haematoma), in addition to the single known
thromboembolic perioperative graft complication (10%)
within the studied group. No incidences of VTE were
reported.
Early acute rejection occurred in half (50%) of the stud-
ied cohort and was successfully managed in all cases using
variable immunological regimens. Subgroup analysis failed
to identify haemodynamic trends measurable by NICOM
or TTFM data, suggestive of a clinically applicable role
for these technologies in the prediction of this com-
plication. Pre-operative TEG data suggested a trend to-
wards a subclinical hypocoagulable state, manifested by
increased reaction time (decreased clot initiation: P = 0.074)
and increased clot lysis at 60 mins (increased fibrinolysis:
P = 0.069) for individuals who subsequently developed
early acute rejection. Further definitive studies would be
required to confirm the significance of these observations
and any possible clinical application.
Power calculations based upon the data of this pro-
spective pilot study suggest that definitive studies asses-
sing the role of NICOM in the perioperative prediction
of DGF should recruit a minimum of n = 67 patients.
Similarly, the authors recommend that a minimum of
n = 20 subjects would be necessary to appraise the role
of TTFM as a quality control tool: predictive of anasto-
motic failure, utilizing a similar study protocol. However,
larger studies would clearly be more descriptive if the
goal was to ascertain a minimum acceptable transplant-
renal artery flow rate at revascularization, as a quality as-
surance technique.
A study sample size of n = 21 subjects would be suffi-
cient to definitively assess the presence or absence of a
hypercoagulable state following allograft reperfusion by
thromboelastography. This number would also permit
subgroup analysis at one year follow-up, to determine if
a role exists for pre-operative TEG values in the predic-
tion of individuals at risk of early acute allograft rejec-
tion and should be pursued.
Key points
1. This pilot study suggests a potential role for
NICOM monitoring in the prediction of individuals
likely to suffer DGF following living-related renal
transplantation, requiring further investigation.
2. There was no apparent correlation between
post-reperfusion transplant renal artery blood flow
(by TTFM) and the development of DGF within
this pilot study.
3. Transplant renal artery TTFM immediately after
reperfusion was significantly reduced in a patient
found to have anastomotic complications. Further
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acceptable’ flow rate, serving as a quality indicator
for anastomosis exploration and revision.
4. Pre-operative TEG was not able to predict that an
individual would experience subsequent thrombotic
complications.
5. TEG demonstrated the presence of a potential
hypercoagulable state following graft reperfusion,
which requires further investigation.
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